Skye Bioscience Inc (SKYE) reports significant advancements in clinical trials and financial stability, despite increased ...

Q2 2025 Management View Punit S. Dhillon, President and CEO, highlighted the imminent reporting of Phase IIa data for ...

Reiterate top-line data readout from CBeyond™ Phase 2a study of nimacimab planned late Q3/early Q4 2025Patient enrollment in ...

Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on advancing new therapeutic ...

Get the latest Skye Bioscience Inc. R (09R.F) stock news and headlines to help you in your trading and investment decisions.

Spruce Biosciences (SPRB) announces a 1-for-75 reverse stock split effective Aug 4, 2025, to meet Nasdaq requirements.

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need.

View the latest Skye Bioscience Inc. (SKYE) stock price, news, historical charts, analyst ratings and financial information from WSJ.